Merck & Company Inc (MRK)vsBio-Techne Corp (TECH)
MRK
Merck & Company Inc
$120.79
-3.46%
HEALTHCARE · Cap: $285.64B
TECH
Bio-Techne Corp
$51.99
-2.24%
HEALTHCARE · Cap: $8.45B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 5332% more annual revenue ($65.77B vs $1.21B). MRK leads profitability with a 13.6% profit margin vs 9.1%. TECH appears more attractively valued with a PEG of 0.74. TECH earns a higher WallStSmart Score of 58/100 (C).
MRK
Hold50
out of 100
Grade: D+
TECH
Buy58
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-49.3%
Fair Value
$80.88
Current Price
$120.79
$39.91 premium
Margin of Safety
+68.6%
Fair Value
$201.82
Current Price
$51.99
$149.83 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Strong operational efficiency at 38.6%
Generating 2.9B in free cash flow
Earnings expanding 128.6% YoY
Safe zone — low bankruptcy risk
Conservative balance sheet, low leverage
Growing faster than its price suggests
Strong operational efficiency at 25.2%
Areas to Watch
Premium valuation, high expectations priced in
4.9% revenue growth
Elevated debt levels
Weak financial health signals
ROE of 5.3% — below average capital efficiency
Weak financial health signals
Premium valuation, high expectations priced in
Revenue declined 1.5%
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.
Bull Case : TECH
The strongest argument for TECH centers on EPS Growth, Altman Z-Score, Debt/Equity. PEG of 0.74 suggests the stock is reasonably priced for its growth.
Bear Case : MRK
The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.
Bear Case : TECH
The primary concerns for TECH are Return on Equity, Piotroski F-Score, P/E Ratio. A P/E of 77.1x leaves little room for execution misses.
Key Dynamics to Monitor
TECH carries more volatility with a beta of 1.36 — expect wider price swings.
MRK is growing revenue faster at 4.9% — sustainability is the question.
MRK generates stronger free cash flow (2.9B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
TECH scores higher overall (58/100 vs 50/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Bio-Techne Corp
HEALTHCARE · BIOTECHNOLOGY · USA
Bio-Techne Corporation develops, manufactures, and sells life science reagents, instruments, and services for the global clinical diagnostic and research markets. The company is headquartered in Minneapolis, Minnesota.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?